Hoth Therapeutics (NASDAQ: HOTH), a patient-focused biopharmaceutical company, has announced the pricing of its underwritten public offering. The offering, consisting of 8,235,294 shares of common stock and priced at the market under Nasdaq requirements, is available at a public offering price of $0.85 per share. Based on that information, the offering should result in approximately $7 million gross proceeds for the company, before standard deductions. Hoth plans on using the proceeds from the offering for working capital and general corporate purposes. The announcement also noted that Hoth granted the underwriters a 45-day option to purchase additional shares. According to the announcement, the offering is expected to close today.
To view the full press release, visit https://ibn.fm/3sN4A
About Hoth Therapeutics Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth’s pipeline development is focused to improve the quality of life for patients suffering from skin toxicities associated with cancer therapy, mast-cell derived cancers and anaphylaxis, Alzheimer’s Disease, atopic dermatitis and other indications. For more information about the company, please visit https://ir.HothRherapeutics.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
